Federal Register Notice: FDA will hold a meeting of the Oncologic Drugs Advisory Committee 9/14, from 8 a.m. to 1 p.m. at the FDA White Oak Campus, 10903 New Hampshire Ave., Bldg. 31 Conference Center, the Great Room (Rm. 1503), Silver Spring, MD. The committee will discuss a Spectrum Pharmaceuticals NDA for apaziquone for intravesical instillation. The proposed indication is for immediate intravesical instillation post-transurethral resection of bladder tumors in patients with non-muscle invasive bladder cancer. Contact Lauren D. Tesh, (301) 796-9001. To view this notice, click here.